Community Health Systems, Inc. Q2 FY2025 earnings call

• Tim Hingtgen announced his retirement at the end of September for personal reasons, planning to step back to spend more time with family. - In the second quarter, same-store net revenue increased 6.5% Y/Y, but patient volumes were lower than expected. - CHS has development strategies including physical capacity and service line expansions, and has recruited over 200 providers for the second half of 2025. - Completed divestiture of Cedar Park Regional Medical Center and refinanced debt. - Kevin Hammons discussed financial results, impact of external factors on demand, progress on strategic initiatives, and analysis of the Big Beautiful Bill's impact on EBITDA and cash flows.

In the second quarter, on a same-store basis, net revenue increased 6.5% year-over-year. Same-store inpatient admissions were up 0.3% year-over-year, while adjusted admissions declined 0.7%. Same-store surgeries declined 2.5% and ED visits were down 1.9%. Adjusted EBITDA for the second quarter was $380 million compared with $387 million in the prior year period. Margins for the second quarter was 12.1% versus 12.3% in the prior year.

• Tightened adjusted EBITDA range for 2025 to $1.45 billion to $1.55 billion. - Projected cumulative impact of Big Beautiful Bill on EBITDA to reduce by $300 million to $350 million over 13 years, with no impact in 2025-2026. - Cash flow guidance considering DPP programs and expected positive cash flow in the back half of the year, with funds from Labcorp sale and contingent payment from Tennova Cleveland expected in the back half.

• Impact of the Big Beautiful Bill on Medicaid reimbursements, including phase-in of lower provider tax thresholds and Medicare-linked rate phase-down. - Uncertainty around Medicaid work requirements, ACA plan enrollment, and distribution of proposed rule funds. - Consumer confidence affecting patient volumes. - Impact of immigration on patient volumes in certain markets like Arizona, Texas, and Florida.

Q: A.J. Rice asked about volumes and cash flow, specifically intra-quarter volume trends and bridging first half cash flow to second half guidance.

A: Kevin Hammons responded that consumer confidence declined from March, volumes started to stabilize in late June, and cash flow from operations in the first half was $282 million, with expectations of positive cash flow in the back half due to DPP programs and fourth quarter cash flow.

Q: Brian Tanquilut asked about EBITDA run rate and Big Beautiful Bill impact.

A: Kevin Hammons said $305 million was too low, with a starting run rate in the $360 million to $375 million range, and explained the state-by-state impact analysis for the Big Beautiful Bill.

Q: Ben Hendrix asked about EBITDA guidance bridge and payer mix.

A: Kevin Hammons recapped the bridge including DPP monies, divestiture impact, and revised back half expectations, and discussed payer mix declines in surgical and commercial Blue Cross business.

Q: Jason Cassorla asked about leverage and divestitures.

A: Kevin Hammons talked about debt maturity, plans to push out 2027 debt, expected proceeds from Labcorp sale and Tennova Cleveland contingent payment, and ongoing divestiture efforts to delever.

Q: Andrew Mok asked about volume drivers and enhanced subsidies.

A: Kevin Hammons mentioned immigration as a potential factor in some markets and stated no estimate on enhanced subsidies impact yet.

Q: Stephen Baxter asked about guidance bridge and Medicare trends.

A: Kevin Hammons explained the guidance bridge components and said Medicare book of business had not seen much change, with low deductible patients least impacted by consumer confidence.

Q: Josh Raskin asked about volume differences and Labcorp deal.

A: Kevin Hammons and Tim Hingtgen discussed possible geographic differences, Tim mentioned investment in physician adviser services, and Kevin talked about Labcorp deal benefits.

Q: Ben Hendrix asked about rural health transformation program.

A: Kevin Hammons said details on rural health transformation program funding were unclear, with 50% at CMS discretion and 50% at state discretion.